Poland· PL-100410692
Vyxeos liposomal
A cytarabine and daunorubicin product containing daunorubicini hydrochloridum + cytarabinum, registered in Poland by Jazz Pharmaceuticals Ireland Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Cytarabine and daunorubicin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XY01 (cytarabine and daunorubicin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Cytarabine and daunorubicin · ATC L01XY01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Daunorubicini hydrochloridum + Cytarabinum
- Manufacturer
- Jazz Pharmaceuticals Ireland Ltd
- Country
- Poland (PL)
- ATC code
- L01XY01
- ATC class
- Cytarabine and daunorubicin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin00368727109827
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cytarabine and daunorubicin in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVYXEOS LIPOSOMALJazz Pharmaceuticals Ireland Ltd, Dublin
- SwitzerlandVyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionsdispersionJazz Pharmaceuticals Switzerland GmbH
- FinlandVyxeos liposomalJazz Pharmaceuticals Ireland Limited
- United KingdomVyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vialsJazz Pharmaceuticals UK Ltd
- IrelandVyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Ireland Limited
- IcelandVyxeos liposomalJazz Pharmaceuticals Ireland Ltd
- NetherlandsVyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusieJazz Pharmaceuticals Ireland Limited
- NorwayVyxeos liposomalJazz Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyxeos Liposomal
- Liechtenstein · Vyxeos Liposomal
- Norway · Vyxeos Liposomal
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab16263a-288e-4143-a5d7-2e4542c255fc GET /v1/drugs/ab16263a-288e-4143-a5d7-2e4542c255fc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "44 mg + 100 mg",
"packaging": "00368727109827 ¦ Rpz ¦ EU/1/18/1308/001 ¦ 129628\n1 fiol. proszku\nRpz ¦ EU/1/18/1308/002 ¦ 129629\n2 fiol. proszku\nRpz ¦ EU/1/18/1308/003 ¦ 129630\n5 fiol. proszku",
"substance": "Daunorubicini hydrochloridum 44 mg + Cytarabinum 100 mg",
"common_name": "Daunorubicini hydrochloridum + Cytarabinum",
"pl_product_id": "100410692",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about cytarabine and daunorubicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.